Category

Brain Disorders

Cannabis use predicts risks of heart failure and cerebrovascular accidents: results from the National Inpatient Sample.

By | Brain Disorders, Cardiovascular Diseases, Medical Cannabis, Nervous System Diseases

Authors: Aditi Kalla, Parasuram Krishnamoorthy, Akshaya Gopalakrishnan, Vincent Figueredo
Journal of Cardiovascular Medicine, September 2018

BACKGROUND: Cannabis for medicinal and/or recreational purposes has been decriminalized in 28 states as of the 2016 election. In the remaining states, cannabis remains the most commonly used illicit drug. Cardiovascular effects of cannabis use are not well established due to a…

Read More

Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes.

By | Anorexia, Behavioral Health, Brain Disorders, Clinical Endocannabinoid Deficiency, Digestive System Diseases, Headache Disorders, Immune System Diseases , Irritable Bowel Syndrome, Multiple Sclerosis, Nervous System Diseases, Parkinsonian Disorders, Stress Disorders - Post-Traumatic

Authors: Ethan B. Russo
Cannabis and Cannabinoid Research, 1 July 2016

Medicine continues to struggle in its approaches to numerous common subjective pain syndromes that lack objective signs and remain treatment resistant. Foremost among these are migraine, fibromyalgia, and irritable bowel syndrome, disorders that may overlap in their affected p…

Read More

Cannabinoids and Epilepsy.

By | Epilepsy

Authors: Evan C. Rosenberg, Richard W. Tsien, Benjamin J. Whalley, Orrin Devinsky
Neurotherapeutics, October 2015

Cannabis has been used for centuries to treat seizures. Recent anecdotal reports, accumulating animal model data, and mechanistic insights have raised interest in cannabis-based antiepileptic therapies. In this study, we review current understanding of the endocannabinoid syst…

Read More

Marijuana Use in Epilepsy: The Myth and the Reality.

By | Epilepsy, Medical Cannabis

Authors: Kamil Detyniecki, Lawrence Hirsch
Current Neurology and Neuroscience Reports, October 2015

Marijuana has been utilized as a medicinal plant to treat a variety of conditions for nearly five millennia. Over the past few years, there has been an unprecedented interest in using cannabis extracts to treat epilepsy, spurred on by a few refractory pediatric cases featured…

Read More

Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.

By | Anorexia, Behavioral Health, Eye Diseases, Feeding and Eating Disorders, Glaucoma, Medical Cannabis, Muscle Spasticity, Muscular Diseases, Pain, Tourette Syndrome

Authors: Penny F. Whiting, Robert F. Wolff, Sohan Deshpande, Marcello Di Nisio, Steven Duffy, et al
JAMA, 23 June 2015

IMPORTANCE: Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms, but their efficacy for specific indications is not clear. OBJECTIVE: To conduct a systematic review of the benefits and adverse events (AEs) of cannabinoids. DATA SOURCES: Twenty…

Read More

Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

By | Brain Disorders, Huntington Disease, Nervous System Diseases, Neurodegenerative Diseases

Authors: Javier Fernández‐Ruiz, Onintza Sagredo, M. Ruth Pazos, Concepción García, Roger Pertwee, et al
British Journal of Clinical Pharmacology, February 2013

Cannabidiol (CBD) is a phytocannabinoid with therapeutic properties for numerous disorders exerted through molecular mechanisms that are yet to be completely identified. CBD acts in some experimental models as an anti-inflammatory, anticonvulsant, anti-oxidant, anti-emetic, an…

Read More

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease.

By | Brain Disorders, Huntington Disease, Nervous System Diseases, Research Articles

Authors: Cristina Blázquez, Anna Chiarlone, Onintza Sagredo, Tania Aguado, M. Ruth Pazos, et al
Brain, January 2011

Endocannabinoids act as neuromodulatory and neuroprotective cues by engaging type 1 cannabinoid receptors. These receptors are highly abundant in the basal ganglia and play a pivotal role in the control of motor behaviour. An early downregulation of type 1 cannabinoid receptor…

Read More

Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

By | Brain Disorders, Digestive System Diseases, General Information, Headache Disorders, Irritable Bowel Syndrome, Medical Cannabis, Muscular Diseases, Nervous System Diseases

Authors: Ethan Budd Russo
Neuroendocrinology Letters, April 2008

OBJECTIVES: This study examines the concept of clinical endocannabinoid deficiency (CECD), and the prospect that it could underlie the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome, and other functional conditions alleviated by clinical cannabis. METHODS:…

Read More